A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03698019

Title field or adapter rule

{'original_value': 'A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:29.757860+00:00

Published At

2023-11-21T00:00:00+00:00

Record Updated At

2026-10-26

Results Posted At

2023-11-21

Source Retrieved At

2026-10-31T22:18:13.198083+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Acral Lentiginous Melanoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Mucosal Melanoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-26", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03698019"

protocolSection.identificationModule.officialTitle

"A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2023-11-21", "type": "ACTUAL"}

Study condition terms

• Acral Lentiginous Melanoma (protocolSection.conditionsModule.conditions)
• Clinical Stage III Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Clinical Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
• Mucosal Melanoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm I (adjuvant pembrolizumab)', 'Arm II (adjuvant and neoadjuvant pembrolizumab)'], 'description': 'Undergo collection of blood', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (adjuvant pembrolizumab)', 'Arm II (adjuvant and neoadjuvant pembrolizumab)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (adjuvant pembrolizumab)', 'Arm II (adjuvant and neoadjuvant pembrolizumab)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (adjuvant pembrolizumab)', 'Arm II (adjuvant and neoadjuvant pembrolizumab)'], 'description': 'Given IV', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (adjuvant pembrolizumab)', 'Arm II (adjuvant and neoadjuvant pembrolizumab)'], 'description': 'Undergo surgery', 'name': 'Therapeutic Conventional Surgery', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.